Morphine derivatives and pharmaceutical compositions thereof
By using a drug composition with a specific ratio of diacylglycerol, phosphatidylcholine, oxygen-containing organic solvents, and organic acids, the problems of instability and insufficient analgesic time of long-acting sustained-release formulations of nalbuphine derivatives have been solved, achieving a longer-acting analgesic effect and better stability.
Patent Information
- Application Number
- CN202410553337.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-08
AI Technical Summary
Existing long-acting sustained-release formulations of nalbuphine derivatives still have shortcomings in terms of stability and analgesic duration, failing to meet the clinical need for prolonged pain relief.
A pharmaceutical composition comprising diacylglycerol, phosphatidylcholine, oxygenated organic solvent and organic acid is formed by storing the components independently in a specific ratio to improve the plasma stability and analgesic duration of nalbuphine derivatives.
It significantly improves the plasma stability and analgesic duration of nalbuphine derivatives, provides a longer-lasting analgesic effect, and reduces crystallization and impurity formation in the pharmaceutical composition, making it suitable for long-acting sustained-release formulations.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to morphine derivatives and pharmaceutical compositions thereof, preparation methods thereof and applications in the pharmaceutical industry. Background Art
[0002] Morphine is an opioid receptor agonist. Morphine and its derivatives are the main drugs for relieving severe pain in clinical practice and are the most widely used powerful analgesics in the world. Nalbuphine is similar in structure to the opioid receptor antagonist naloxone and the powerful opioid analgesic oxymorphone. It mainly exerts its pharmacological effects by stimulating κ receptors and antagonizing μ receptors. Its analgesic potency is similar to that of morphine, but it has fewer side effects and is safer. It is mainly used to treat moderate to severe pain. Nalbuphine can take effect within 2 to 3 minutes after intravenous administration, and within 15 minutes after intramuscular or subcutaneous injection. The onset plasma concentration is 12 μg / L, and the peak plasma concentration reaches 48 μg / L in 30 minutes. The half-life is about 5 hours. Depending on individual differences, the analgesic time is about 3 to 6 hours (see Beaver, WT, Feise, GA and Robb, D. (1981) Analgesic Effect of Intramuscular and Oral Nalbuphine in Postoperative Pain. Clinical Pharmacology and Therapeutics, 29, 174-180.). Therefore, for patients with severe or persistent pain, frequent injections or administration of nalbuphine are required.
[0003] Dinalbuphine sebacate (DNS), also known as senabuphine, is a dimer of nalbuphine. Its chemical structure is shown below:
[0004]
[0005] Senabuphine is a prodrug of nalbuphine formed by two nalbuphine molecules connected to a sebacyl group through an ester bond. It has no analgesic activity itself. After entering the blood, it is hydrolyzed into the active ingredient nalbuphine to exert an analgesic effect. Senabuphine is more lipid-soluble than nalbuphine and can be dissolved in the excipients of long-acting sustained-release preparations to be prepared into long-acting preparations. However, nalbuphine has better hydrophilicity and lower solubility in the excipients of long-acting preparations, making it unsuitable for the preparation of long-acting preparations. Currently, the long-acting sustained-release preparation of senabuphine has been launched in Taiwan, China. The analgesic effect of a single use is up to 7 days. It can be used to relieve moderate to severe pain after surgery and has the characteristics of strong and long-acting analgesia. Clinically, there is still a need for drugs with prolonged analgesia to continuously relieve patients' pain.
[0006] Patent WO2023020608 discloses an improved preparation of senabuphine, which comprises acylglycerol, phosphatidylcholine, at least one oxygen-containing organic solvent, at least one acid and senabuphine. The obtained pharmaceutical composition has higher stability, faster onset, longer duration of action, and can reduce injection pain and reduce hemolysis. At present, there is still a need to provide a morphine derivative with a longer analgesic effect and a pharmaceutical composition thereof to relieve the patient's pain and meet the unmet clinical needs. Summary of the invention
[0007] In order to solve the problems existing in the prior art, the present invention provides novel nalbuphine prodrug compounds with better plasma stability and longer analgesic time, as well as pharmaceutical compositions containing these compounds.
[0008] Pharmaceutical composition
[0009] First, the present invention provides a pharmaceutical composition comprising a compound of general formula I, wherein the pharmaceutical composition comprises (a) diacylglycerol, (b) phosphatidylcholine, (c) an oxygen-containing organic solvent, (d) at least one organic acid and (e) the compound of general formula I;
[0010] Wherein, the compound represented by the general formula I has the following structure:
[0011]
[0012] Wherein, R1 is selected from: C9-15 straight chain or branched chain alkyl, or H;
[0013] R2 is selected from: C 1~6 Straight or branched alkyl, C 3~6 Cycloalkyl, C 2~6 Alkenyl or H;
[0014] In a preferred embodiment of the present invention, the compound represented by the general formula I, wherein R1 is selected from a C9 straight chain or branched alkyl group, C 10 A straight or branched alkyl group, C 11 A straight or branched alkyl group, C 12 A straight or branched alkyl group, C 13 A straight or branched alkyl group, C 14 A straight or branched chain alkyl group, or C 15 A straight chain or branched chain alkyl group.
[0015] In a preferred embodiment of the present invention, the compound represented by the general formula I, wherein R2 is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or vinyl.
[0016] In a preferred embodiment of the present invention, the compound represented by the general formula I, wherein R1 is selected from C 15 of a straight chain alkyl group.
[0017] In a preferred embodiment of the present invention, in the compound represented by the general formula I, R2 is selected from cyclobutyl.
[0018] In a more preferred embodiment of the present invention, the compound represented by the general formula I is selected from the following compounds:
[0019]
[0020] In a preferred embodiment, the pharmaceutical composition of the present invention, wherein in method A, the (a) diacylglycerol, (b) phosphatidylcholine and part of (c) oxygen-containing organic solvent are the first component of the pharmaceutical composition, and the remaining (c) oxygen-containing organic solvent, (d) at least one organic acid and (e) the compound represented by general formula I are the second component of the pharmaceutical composition; or in method B, (a) diacylglycerol, (b) phosphatidylcholine, (c) oxygen-containing organic solvent and (d) at least one acid are the first component of the pharmaceutical composition, and (e) the compound represented by general formula I is the second component of the pharmaceutical composition, and the first component and the second component are stored separately;
[0021] Further preferably, the weight ratio of the oxygen-containing organic solvent in the first component to the second component in method A is (0.2-2):1, such as 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.8:1, 1:1, 1.5:1 or 2:1.
[0022] In a preferred embodiment, in the pharmaceutical composition of the present invention, the acyl group of (a) diacylglycerol is selected from lauroyl (C12:0), myristoyl (C14:0), palmitoyl (C16:0), phytanoyl (C16:0), palmitoleoyl (C16:1), stearoyl (C18:0), oleoyl (C18:1), elaidoyl (C18:1), linoleoyl (C18:2), linolenoyl (C18:3), arachidonic acid (C20:4), behenoyl (C22:0) and tetracosanoyl (C24:9), preferably oleoyl.
[0023] In one embodiment of the present invention, the acyl group is based on natural fatty acids, including but not limited to lauric acid, myristic acid, palmitic acid, phytanic acid, palmityl acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, arachidonic acid, behenic acid or lignoceric acid. The preferred source of the acyl group is palmitic acid, stearic acid, oleic acid and linolenic acid, particularly, preferably oleic acid.
[0024] In one embodiment of the present invention, the diacylglycerols comprise at least 50 wt% of glyceryl dioleate (GDO), preferably at least 80 wt% of GDO, more preferably substantially all of the diacylglycerols are GDO.
[0025] Typically, GDO and other diacylglycerols are present in a certain proportion of "impurity" esters with other chain lengths, etc. Thus, in one aspect, GDO as used herein is used to refer to any commercial grade of GDO (i.e., commercial purity GDO) containing accompanying impurities. These impurities can be separated and removed by purification, but such purification is rarely necessary if the grade is consistent. However, if necessary, "GDO" can be substantially chemically pure GDO, such as GDO that is at least 80% pure, preferably at least 85% pure, and more preferably at least 90% pure.
[0026] In one embodiment of the present invention, the (b) phosphatidylcholine (abbreviation, PC) may be derived from a natural source. Suitable sources of phosphatidylcholine (PC) include egg, heart (e.g., bovine), brain, liver (e.g., bovine) and plant sources including soybeans. Such sources may provide one or more components of (b) phosphatidylcholine, which may contain any mixture of phospholipids. Any single PC or mixture of PC from these or other sources may be used, but a mixture containing soybean PC or egg PC is very suitable, whereby the phosphatidylcholine of the present invention is selected from at least one of egg PC, heart PC, brain PC, liver PC, egg yolk PC or soybean PC, preferably at least one of egg PC, egg yolk PC or soybean PC, more preferably soybean PC.
[0027] In a preferred embodiment, a particularly advantageous combination of (a) diacylglycerols and (b) phosphatidylcholine is GDO and PC, in particular GDO and soy PC.
[0028] In one embodiment of the present invention, the content of diacylglycerol (a) is 40-65% by weight, for example, 40-45% by weight, 40-50% by weight, 40-55% by weight, 40-60% by weight, 40-65% by weight, 45-50% by weight, 45-55% by weight, 45-60% by weight, 45-65% by weight, 50-55% by weight, 50-60% by weight, 50-65% by weight, 55-60% by weight, 55-65% by weight, 60-65% by weight, etc. and all ranges included therein; further by way of example, the content of diacylglycerol (a) is 40-65% by weight, for example, 40-50% by weight, 40-55% by weight, 40-60% by weight, 40-65% by weight, 45-50% by weight, 45-55% by weight, 45-60% by weight, 45-65% by weight, 50-55% by weight, 50-60% by weight, 50-65% by weight, 55-60% by weight, 55-65% by weight, 60-65% by weight, etc. and all ranges included therein; The acylglycerols may be present in the pharmaceutical composition in an amount of about 40 wt%, about 41 wt%, about 44 wt%, about 45 wt%, about 46 wt%, about 47 wt%, about 48 wt%, 49 wt%, about 50 wt%, 51 wt%, 52 wt%, 53 wt%, 54 wt%, 55 wt%, 56 wt%, 57 wt%, 58 wt%, 59 wt%, 60 wt% or about 61 wt%, and the like, and ranges between any two values thereof; preferably, the content of (a) diacylglycerols is 50-60 wt%, more preferably 54-58 wt%.
[0029] The content of the (b) phosphatidylcholine is 4-15% by weight, for example, 4-10% by weight, 10-15% by weight, 4-6% by weight, 4-8% by weight, 4-9% by weight, 5-6% by weight, 5-7% by weight, 5-8% by weight, 5-9% by weight, 5-10% by weight, 5-15% by weight, or 8-15% by weight, etc., and all ranges included therein; further by way of example, the (b) phosphatidylcholine may be present in the pharmaceutical composition in the following amounts: about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, about 15% by weight, and ranges between any two of the values; preferably, the content of the (b) phosphatidylcholine is 4-10% by weight, more preferably 5-8% by weight.
[0030] The first component including an oxygen-containing organic solvent is beneficial for reducing the viscosity of the composition; the second component including an oxygen-containing organic solvent is beneficial for fully mixing the active ingredient compound represented by general formula I with the acid, thereby increasing the storage stability of the compound represented by general formula I. In one embodiment, (c) the oxygen-containing organic solvent is selected from amides, C 1-3 The amide is selected from at least one of N-methylpyrrolidone (NMP), dimethylformamide, 2-pyrrolidone and dimethylacetamide (DMAC, also known as N,N-dimethylacetamide); the C 1-3The alcohol is selected from methanol, ethanol, isopropanol or propanol. The inventors have found through research that the stability of the compound represented by general formula I in NMP and DMAC is better than other oxygen-containing organic solvents, and preferably (c) the oxygen-containing organic solvent is N-methylpyrrolidone and / or dimethylacetamide.
[0031] In the pharmaceutical composition, the total amount of the oxygen-containing organic solvent is: 15-50% by weight, for example, 15-45% by weight, 30-45% by weight, 40-45% by weight, 15-40% by weight, 16-40% by weight, 20-40% by weight, 25-40% by weight, 30-40% by weight, 35-40% by weight, 15-35% by weight, 15-34% by weight, 20-35% by weight, 25-35% by weight, 30-35% by weight, 15-30% by weight, 20-30% by weight, 25-30% by weight, 15-25% by weight, 20-25% by weight, 15-20% by weight, 15-35% by weight, etc., and all ranges included therein; as an example, the total amount of the oxygen-containing organic solvent in component (c) is: for example, about 15% by weight %, about 20 wt %, about 25 wt %, about 26 wt %, about 27 wt %, about 28 wt %, about 29 wt %, about 30 wt %, about 31 wt %, about 32 wt %, about 33 wt %, about 34 wt %, about 35 wt %, about 36 wt %, about 37 wt %, about 38 wt %, about 39 wt %, about 40 wt % and ranges between any two of the values thereof; preferably 20 to 35 wt %; wherein in method A, the weight ratio of the oxygen-containing organic solvent in the first component to the second component relative to the total weight of (a), (b), (c), (d) and (e) is (0.2 to 2):1, such as 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.8:1, 1:1, 1.5:1 or 2:1. It is further preferred that, relative to the total weight of (a), (b), (c), (d) and (e), the content of oxygen-containing organic solvent in the first component in method A is 5 to 15 weight %, such as about 5 weight %, about 6 weight %, about 7 weight %, about 8 weight %, about 9 weight %, about 10 weight %, about 11 weight %, about 12 weight %, about 13 weight %, about 14 weight %, about 15 weight %, etc., and the content of oxygen-containing organic solvent in the second component is 10 to 30 weight %, such as about 10 weight %, about 15 weight %, about 16 weight %, about 17 weight %, about 18 weight %, about 19 weight %, about 20 weight %, about 21 weight %, about 22 weight %, about 23 weight %, about 24 weight %, about 25 weight %, etc.
[0032] In a specific embodiment, in the above-mentioned pharmaceutical composition, the content of the compound represented by the general formula I is 5 to 20% by weight, for example: 7 to 15% by weight, 10 to 15% by weight, 7.5 to 15% by weight, 7.5 to 12.5% by weight, 7.5 to 10% by weight, 8 to 10% by weight, 8 to 11% by weight, 9 to 11% by weight, 9 to 10% by weight, 15 to 18% by weight, 15 to 20% by weight, about 7.5% by weight, about 7.9% by weight, about 8% by weight, about 8.2% by weight. , about 9.2 weight %, about 9.5 weight %, about 10 weight %, about 10.5 weight %, about 10.6 weight %, about 11 weight %, about 11.5 weight %, about 12 weight %, about 14 weight %, about 15 weight %, about 16 weight %, about 17 weight %, about 18 weight %, about 19 weight %, about 20 weight % and the range between any two values, preferably the content of the compound represented by general formula I is 7 to 15 weight %, more preferably 8 to 12 weight %, and further preferably 9 to 11 weight %.
[0033] In a specific embodiment, the acid (d) is at least one of methanesulfonic acid, maleic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, and citric acid. The addition of acid is beneficial to improving the storage stability of the compound represented by general formula I. The increase in stability can be demonstrated by the following: when the pharmaceutical composition contains the acid (especially methanesulfonic acid) described in the present invention, its chemical stability is significantly improved, which is reflected in less degradation of impurities; the increase in stability is also reflected in the increase in physical stability, which is specifically reflected in that the addition of acid (especially methanesulfonic acid) can significantly reduce the crystallization problem of the compound represented by general formula I in the pharmaceutical composition. Therefore, it is preferred that (d) includes methanesulfonic acid. The molar ratio of the compound represented by general formula I to methanesulfonic acid is 1.2 to 2.2:1, which is advantageous, especially the molar ratio of the compound represented by general formula I to organic acid is 1.2 to 2.2:1, preferably 1.8 to 2.2:1, for example 2:1. The content of maleic acid is 0 to 0.2% by weight, for example 0 to 0.02% by weight, or 0 to 0.01% by weight, etc.
[0034] In a preferred embodiment, the pharmaceutical composition, wherein the content of the compound represented by the general formula I is 5 to 20% by weight, preferably 7 to 15% by weight; preferably, the compound represented by the general formula I is compound I16a;
[0035] The content of diacylglycerol is 40 to 65% by weight, preferably 50 to 60% by weight;
[0036] The content of phosphatidylcholine is 4 to 15% by weight, preferably 4 to 10% by weight;
[0037] The molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1;
[0038] The content of the oxygen-containing organic solvent is 15 to 50% by weight, preferably 20 to 35% by weight;
[0039] The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e).
[0040] In a preferred embodiment, the pharmaceutical composition, wherein the content of the compound represented by the general formula I is 5 to 10% by weight; preferably, the compound represented by the general formula I is compound I16a;
[0041] The content of diacylglycerol is 50-60% by weight;
[0042] The content of phosphatidylcholine is 4 to 10% by weight;
[0043] The content of the oxygen-containing organic solvent is 20 to 35% by weight;
[0044] The molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1;
[0045] The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e).
[0046] In a preferred embodiment, the pharmaceutical composition, wherein (a) the diacylglycerol is diolein;
[0047] (b) the phosphatidylcholine is selected from at least one of egg PC, heart PC, brain PC, liver PC, egg yolk PC or soybean PC, preferably at least one of egg PC, egg yolk PC or soybean PC, more preferably soybean PC;
[0048] (c) the oxygen-containing organic solvent is selected from amides, C 1-3 At least one of alcohols or benzyl alcohol, the amides are selected from at least one of N-methylpyrrolidone, dimethylformamide, 2-pyrrolidone and dimethylacetamide, preferably N-methylpyrrolidone and / or dimethylacetamide;
[0049] (d) The organic acid is at least one of methanesulfonic acid, maleic acid, p-toluenesulfonic acid, acetic acid, fumaric acid and citric acid, preferably at least one of methanesulfonic acid or maleic acid.
[0050] In a preferred embodiment, the pharmaceutical composition of the present invention, wherein the diacylglycerol is selected from diolein; the phosphatidylcholine is selected from soybean phosphatidylcholine; the oxygen-containing organic solvent is selected from DMAC and / or NMP; the organic acid is selected from methanesulfonic acid, and optionally further comprises maleic acid.
[0051] In a specific embodiment, the present invention provides a pharmaceutical composition, comprising a first component and a second component, and the first component and the second component are stored separately, wherein the first component comprises 50-60% by weight of diolein, 4-15% by weight of soybean PC and 5-15% by weight of dimethylacetamide; the second component comprises 10-30% by weight of dimethylacetamide, 7-15% by weight of the compound represented by general formula I; and methanesulfonic acid, optionally further comprising maleic acid;
[0052] Alternatively, the first component comprises 50-60 wt% of dioleyl glycerol, 4-15 wt% of soybean PC, 20-35 wt% of dimethylacetamide, and methanesulfonic acid, and optionally further comprises maleic acid; the second component comprises 7-15 wt% of the compound represented by general formula I;
[0053] The molar ratio of the compound represented by the general formula I to methanesulfonic acid is 1.2-2.2:1, and the content of maleic acid is 0-0.01%.
[0054] In another specific embodiment, the present invention provides a pharmaceutical composition comprising:
[0055] 7 to 15% by weight of a compound of formula I, preferably the compound of formula I is compound I16a;
[0056] 20 to 35% by weight of dimethylacetamide;
[0057] 50-60% by weight of diolein;
[0058] 4 to 15% by weight of soybean PC; and methanesulfonic acid, optionally also including maleic acid;
[0059] The molar ratio of the compound represented by the general formula I to methanesulfonic acid is 1.2-2.2:1, and the content of maleic acid is 0-0.01%.
[0060] In another specific embodiment, the present invention provides a pharmaceutical composition comprising:
[0061] 10-11 wt% of compound I16a;
[0062] 29-30% by weight of dimethylacetamide;
[0063] 55-60% by weight of diolein;
[0064] 5-6 wt% soybean PC; and methanesulfonic acid;
[0065] The molar ratio of compound I16a to methanesulfonic acid is 1.3-2:1.
[0066] In another specific embodiment, the present invention provides a pharmaceutical composition, comprising a first component and a second component, wherein the first component comprises 55-60% by weight of dioleyl glycerol, 5-6% by weight of soybean PC, and 5-11% by weight of dimethylacetamide; the second component comprises 19-25% by weight of dimethylacetamide; 10-11% by weight of compound I16a; and methanesulfonic acid; wherein the molar ratio of compound I16a to methanesulfonic acid is 1.3-2:1;
[0067] Further preferably, the first component and the second component are stored separately, preferably separately in vials.
[0068] In a preferred embodiment, the pharmaceutical composition of the present invention comprises a first component and a second component, the first component is stored in a first container, and the second component is stored in a second container; or the first component and the second component are respectively loaded into different compartments of a dual-compartment dispensing device for storage.
[0069] In one embodiment of the present invention, the first component is stored in a first container, and the second component is stored in a second container, wherein the first container and the second container are each independently selected from a vial, an ampoule or a prefilled syringe, the prefilled syringe is a single-chamber, and preferably the prefilled syringe is a prefilled Luer lock syringe; for example, the first component and the second component are respectively stored in two independent vials; or the first component and the second component are respectively stored in two independent ampules; or one of the first component and the second component is stored in a vial, and the other component is stored in an ampoule; or the first component and the second component are respectively stored in two independent prefilled syringes, the prefilled syringe is a single-chamber, and preferably the prefilled syringe is a prefilled Luer lock syringe.
[0070] In one embodiment of the present invention, the pharmaceutical composition comprising the first component and the second component described in the present invention can also be stored in a double-chamber prefilled syringe, wherein the double-chamber prefilled syringe comprises a front chamber and a rear chamber, and the first component is stored in the front chamber and the second component is stored in the rear chamber, or the first component is stored in the rear chamber and the second component is stored in the front chamber; preferably, the second component is stored in the front chamber and the first component is stored in the rear chamber.
[0071] In one embodiment of the present invention, in the pharmaceutical composition of the present invention, the compound represented by the general formula I is selected from:
[0072]
[0073] The pharmaceutical composition comprising the first component and the second component of the present invention is a lyophilized powder injection, and is more preferably in the form of a final "ready-to-use medicine", also known as a "single dose" form, or a "unit preparation". Before use of the pharmaceutical composition, the first component and the second component are mixed, and the mixing method is not limited, and the mixing can be performed by any method known in the art. For example, when the first component and the second component are stored in the first container and the second container respectively, the first component can be sucked into the container containing the second component by a syringe, or all the liquid medicine can be sucked from the container (such as a vial) where the second component is located, transferred to the container (such as a vial) where the first component is located, shaken, visually observe that the liquid medicine becomes a homogeneous liquid medicine, remove bubbles in the liquid medicine, and suck all the liquid medicine with a syringe (such as an 18G needle), and replace the syringe needle. The first component and the second component are respectively stored in two independent prefilled syringes, such as prefilled Luer lock syringes, and the method of mixing the two components is also commonly used in the art, such as connecting the syringes containing the first component and the second component through a connector, such as screwing the two syringe Luer lock connectors onto the threads at both ends of the connector, and then slowly pushing the mixed solution back and forth in the two syringes until it is evenly mixed. The Luer lock syringes described above are currently commercial products that can be used, such as Luer lock syringes, Prefilled Luer Lock Polymer Syringes, HypakSCF from BD Healthcare TM PRTC glass prefilled syringe, Hylok TM Pre-filled systems, etc.
[0074] The dual-chamber prefilled syringe of the present invention is a dual-chamber syringe that also serves as a container. In such a dual-chamber prefilled syringe, a front plug is usually inserted into the front end side of the outer barrel, a rear plug is inserted into the rear end side of the outer barrel, and a middle plug is inserted into the central part of the outer barrel, so that the interior of the outer barrel is divided into a front chamber and a rear chamber. The present invention does not limit the specific structure of such dual-chamber prefilled syringes, and any dual-chamber prefilled syringes that meet pharmaceutical standards known in the art are applicable to the present invention.
[0075] In the embodiment provided by the present invention, by adding an acid, especially methanesulfonic acid, the problem of crystallization and suspension of the compound represented by general formula I in the preparation composition is solved, and the generation of degradation impurities in the pharmaceutical composition is suppressed, thereby significantly improving the stability of the compound represented by general formula I in the pharmaceutical composition.
[0076] The compound represented by the general formula I provided by the present invention, especially nalbuphine palmitate, has better stability in plasma and has the potential for longer effect than senabuphine; in addition, the pharmaceutical composition obtained by providing a specific auxiliary material ratio in the embodiment of the present invention not only has the advantages of slow release and sustained effect, but also has the advantages of good compatibility of raw materials and auxiliary materials, high stability of the pharmaceutical composition, and less impurity degradation.
[0077] Application
[0078] The pharmaceutical composition provided by the present invention is preferably administered parenterally. Administration will be performed by injection, such as any method by which the preparation is passed through the skin by a needle, catheter or needleless syringe. In a preferred embodiment of the present invention, the pharmaceutical composition is stored in a final dosage unit, and before use, the first component and the second component are mixed into a homogeneous liquid and delivered to a mammal (preferably a human) by a needle, preferably by subcutaneous (sc) or intramuscular (im) injection. The pharmaceutical composition of the present invention is also suitable for intracavitary administration, or by deeply buried in the subcutaneous formation of a reservoir preparation. The inventors observed through experiments that after the pharmaceutical composition provided by the present invention is administered, the active ingredient can be released in a sustained manner, and a sustained effect is exerted. Since the pharmaceutical composition of the present invention can form a gel reservoir at the injection site after being administered in vivo, the release time is allowed to be extended. A longer stable release cycle meets the needs of patient comfort and compliance.
[0079] The unit injection volume of the pharmaceutical composition provided by the present invention is preferably no more than 3 mL / each administration, more preferably no more than 2.5 mL / each administration, 2 mL / each administration, 1.8 mL / each administration, 1.5 mL / each administration, 1 mL / each administration, etc. The pharmaceutical composition provided by the present invention comprising the first component and the second component is preferably a unit preparation for final administration, that is, a standard dose injection, the unit preparation contains at least 50 to 200 mg of the compound of formula I, preferably 100 to 200 mg, such as 100 mg, 120 mg, 150 mg, 180 mg or 200 mg, etc., preferably the unit preparation contains 120 to 150 mg of the compound of formula I, especially 150 mg; further preferably, the volume of the unit preparation of the pharmaceutical composition is about 3 mL / tube, about 2 mL / tube, about 1.9 mL / tube, about 1.8 mL / tube, about 1.5 mL / tube, about 1 mL / tube or about 0.5 mL / tube and any value therebetween.
[0080] Further preferably, the total volume of the first component and the second component of the pharmaceutical composition after mixing is 0.5-3 ml, such as 0.5 ml-1.0 ml, 0.5 ml-1.5 ml, 1.0 ml-1.5 ml, 1-2 ml, 1.5-2.0 ml, 1.8-2.0 ml, 2.0 ml-3.0 ml, about 0.5 ml, about 1.0 ml, about 1.5 ml, about 1.8 ml, about 2.0 ml, etc.; more preferably 0.5 ml-1.5 ml, wherein the content of the compound represented by the general formula I is about 50 mg, or about 100 mg, or about 150 mg, or about 180 mg, or about 200 mg, etc. The "unit preparation" described in the present invention has the conventional meaning in the art, and refers to the smallest dosing unit or the smallest payment unit or the smallest packaging unit that can be split in the drug. For injections, the unit preparation is a dose of one.
[0081] On the other hand, pharmaceutical composition provided by the invention can be applied by disposable drug delivery device (optionally, also comprising device assembly).Such device will usually contain a single dose prepared for application, and is usually aseptically packaged, so that the pharmaceutical composition is stored in the device until administration.Disposable drug delivery device suitable for the present invention for example includes cartridges, ampoules, and particularly syringes, with integral needles or with needles (such as Luer (luer)) joints suitable for the dual chamber prefilled syringes adopted.Similar devices include needle-free syringes, multiple use or single use syringes and dual chamber prefilled syringe combinations, cartridges, or vials, or vials, or ampoules and syringes and / or injection needles and accessories thereof.
[0082] Specifically, the disposable drug delivery device may include two independent containers, and the size and shape of the two independent containers are not limited, as long as they can meet the sterility and regulatory requirements and usage requirements for the quality of pharmaceutical excipients and packaging materials. For example, the size of the container can be determined according to the volume of the first component and the second component in the pharmaceutical composition. According to the preferred dosage and volume of the aforementioned pharmaceutical composition of the present invention, the size of the container is preferably 0.5 to 5 ml, for example, about 0.5 ml, about 1 ml, about 1.5 ml, about 2 ml, about 2.5 ml, 3 ml, about 3.5 ml, about 4 ml or 5 ml, etc.
[0083] In a preferred embodiment of the present invention, the container is a vial, such as a vial and / or an ampoule, or the container is a prefilled syringe, the prefilled syringe is a single-chamber syringe, and preferably the prefilled syringe is a prefilled Luer lock syringe. The first component and the second component in the pharmaceutical composition of the present invention are respectively placed in two vials, such as vials and / or ampoules, that is, the first component can be stored in one vial and the second component can be stored in another vial or ampoule, or the first component can be stored in one ampoule and the second component can be stored in another ampoule or vial; the drug delivery device also includes a syringe, a syringe and a syringe syringe, and optionally also includes an injection needle, such as an 18G needle and / or a 23G needle. The devices included in the drug delivery device should be able to meet the requirements of at least one-time injection administration. For example, when the pharmaceutical composition is administered, it is necessary to use a syringe to transfer one component to another component and mix them evenly, and then administer it to an individual through a syringe. In a preferred embodiment, before administration, the first component is transferred to the container where the second component is located and mixed, or the second component is transferred to the container where the first component is located and mixed, and then administered to an individual through a syringe.
[0084] In a specific embodiment, for example, the pharmaceutical composition includes a first component and a second component, each of which is stored in a 2 ml vial. Those skilled in the art can adjust the method of use of the pharmaceutical composition of the present invention according to the needle-passing results, the convenience of clinical use, and the patient's acceptability, as well as the difficulty of absorbing and injecting each component. For example, use a 2 ml 18G syringe to absorb all the liquid medicine from the first component, transfer it to the vial (such as a vial) where the second component is located, shake for 1 min to 3 min, visually observe that the liquid medicine becomes a homogeneous liquid medicine, let it stand for about 5 min to eliminate the bubbles in the liquid medicine, use a 2 ml 18G syringe to absorb all the liquid medicine, replace the syringe needle with a 23G needle, and inject it into the patient.
[0085] In another embodiment, the disposable drug delivery device comprises a double-chamber prefilled syringe, wherein the first component and the second component of the pharmaceutical composition of the present invention are respectively placed in two different chambers of the double-chamber prefilled syringe, preferably, the second component is located in the front chamber of the double-chamber prefilled syringe, and the first component is located in the rear chamber. Optionally, the drug delivery device also has standard accessories suitable for disposable injection using a double-chamber syringe.
[0086] The dual-chamber prefilled syringe described in the present invention is consistent with the common understanding of those skilled in the art, such as the dual-chamber syringe prefilled for Abilify Maintena. For this type of dual-chamber prefilled syringe, there are already commercial products in the art that meet clinical use. In addition, any similar dual-chamber prefilled syringe that has been disclosed before the date of this application is suitable for the present invention, such as the dual-compartment product for aseptic mixing of substances disclosed in CN102482023A.
[0087] In another embodiment, the disposable drug delivery device may also use a prefilled syringe, which is a single-chamber syringe. Preferably, the prefilled syringe is a prefilled Luer lock syringe. The first component and the second component are respectively prefilled in the prefilled syringe, such as a prefilled Luer lock syringe. The drug delivery device should also include a connector that matches the Luer lock thread of the prefilled Luer lock syringe. Both ends of the connector have threads, and a prefilled Luer lock syringe containing the first component and a prefilled Luer lock syringe containing the second component can be connected through the connector, and then the first component and the second component can be evenly mixed in the two syringes. In addition, it also includes a needle and other accessories used in conjunction with the prefilled Luer lock syringe, so that the drug delivery device can at least meet the needs of disposable injection.
[0088] Therapeutic Uses
[0089] Another aspect of the present invention provides use of the pharmaceutical composition in preparing a drug for treating pain.
[0090] The present invention also provides a method for treating pain, comprising administering the pharmaceutical composition of the present invention to a subject in need thereof (eg, a mammalian subject, such as a human).
[0091] The pain of the present invention is selected from surgical pain or long-term chronic pain. The surgical operation includes but is not limited to common types of general surgery, such as hernia surgery, hemorrhoid surgery, abdominal surgery, plastic surgery, orthopedic surgery, ENT surgery, etc.; the long-term chronic pain includes but is not limited to cancer pain, chronic back pain and chronic joint pain, etc. Unless otherwise specified, all percentages herein are weight ratios. The preformulation may consist essentially of only these components, and in one aspect consists entirely of these components.
[0092] Preparation method of pharmaceutical composition:
[0093] The present invention provides a method for preparing the pharmaceutical composition, the method comprising:
[0094] Method S1: adding the compound of formula I and an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then adding acylglycerol, and finally adding phosphatidylcholine, and dissolving them to obtain the product; or,
[0095] Method S2: first add an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then add acylglycerol and phosphatidylcholine in sequence, stirring and dissolving, and finally add the compound represented by general formula I, stirring and dissolving to obtain the product; or,
[0096] Method S3: adding diacylglycerol in a prescribed ratio to a portion of an oxygen-containing organic solvent, and then adding phosphatidylcholine, stirring and dissolving, as a first component;
[0097] Add the organic acid in the prescribed ratio to the remaining amount of the oxygen-containing organic solvent and stir to mix, then add the compound represented by the general formula I and dissolve and mix to form the second component. Alternatively,
[0098] Method S4: adding an organic acid in a prescribed ratio to an oxygen-containing organic solvent and stirring to mix well, then adding acylglycerol and phosphatidylcholine and stirring to dissolve, as a first component;
[0099] The compound represented by the general formula I in the prescribed proportion is used as the second component.
[0100] In some embodiments of the present invention, the preparation method further comprises filtering and sterilizing the prepared composition by passing it through a 0.22 μm sterile filtration membrane.
[0101] In a specific embodiment, the method for preparing the pharmaceutical composition comprises the following steps:
[0102] Dissolve the compound of formula I, methanesulfonic acid and optionally maleic acid in dimethylacetamide (or NMP) in a prescribed ratio, then add dioleylglycerol and stir, and finally add soybean PC and dissolve to obtain; or,
[0103] According to the prescription ratio, methanesulfonic acid and optional maleic acid are first dissolved in dimethylacetamide (or NMP), then diolein is added and stirred, then soybean PC is added and stirred to dissolve, and finally the compound represented by general formula I is added and stirred to dissolve.
[0104] Preferably, in the above method, when phosphatidylcholine is added for dissolution, the mixture is first heated to a temperature not exceeding 45° C., preferably to 40° C., which can significantly accelerate the dissolution rate.
[0105] In another specific embodiment, the method for preparing the pharmaceutical composition comprises the following steps:
[0106] Add GDO in the prescribed proportion to part of DMAC or NMP, then add soybean lecithin, stir and dissolve, as the first component;
[0107] Add methanesulfonic acid in the prescribed ratio to the remaining amount of DMAC or NMP and stir to mix, then add the compound of formula I and dissolve and mix to form the second component; or,
[0108] Add methanesulfonic acid in the prescribed ratio to DMAC or NMP and stir to mix, then add GDO and soybean lecithin and stir to dissolve as the first component;
[0109] The compound represented by the general formula I in the prescribed proportion is used as the second component.
[0110] In a specific embodiment, the method further includes storing the first component and the second component separately and independently, for example, the first component and the second component are stored separately from each other in different container devices (such as vials, such as vials, ampoules, etc., or prefilled syringes such as prefilled Luer lock glass syringes); or the first component and the second component are respectively loaded into different compartments of a dual-compartment dispensing device (dual-chamber prefilled syringe) for storage, etc., and the different containers and the dual-compartment dispensing device are as described in the context of the present invention.
[0111] In some embodiments of the present invention, the preparation method of the present invention further comprises filtering and sterilizing the prepared first component and / or second component by passing through a 0.22 μm sterile filtration membrane.
[0112] Compounds of general formula I and preparation methods thereof
[0113] Method 1: The present invention provides a method for preparing a compound of formula I, comprising reacting compound I01 (such as nalbuphine) with a carboxyl-containing compound R1-COOH in a suitable organic solvent (such as dichloromethane, DMF, DMSO, dioxane, ethyl acetate, NMP or DMAC, etc.) to obtain a compound of formula I (such as an alkyl ester of nalbuphine), wherein R1 and R2 are as defined above in the present invention. It is further preferred that R1COOH is some saturated fatty acid CH3(CH2) m1 COOH, wherein m1 is an integer from 9 to 15, such as lauric acid, palmitic acid, etc.
[0114]
[0115] Method 2: The compound represented by the general formula I described in the present invention can also be prepared by reacting compound I02 with a carboxyl-containing compound R1-COOH in a suitable organic solvent (such as dichloromethane, DMF, DMSO, 1,2-hexadecane, ethyl acetate, NMP or DMAC, etc.) to obtain compound I03, and then performing a reduction reaction to obtain the compound represented by the general formula I.
[0116]
[0117] wherein R1 and R2 are as defined above in the present invention.
[0118] In another aspect of the present invention, a novel compound is provided, wherein the compound has the following structure:
[0119]
[0120] In the present invention, the parameter range selection includes the endpoint values, for example, 5-20% by weight includes the endpoint values "5%" and "20%"; the ratio range 1.2-2.2:1 includes "1.2:1" and "2.2:1". In particular, when referring to a given numerical value, the terms "about" and "around" indicate that the specified amount is a primary embodiment, but the actual amount should not differ significantly from the specified amount, as judged by a person skilled in the art. Unless prohibited by the context, this will generally be ±10%, ±5%, ±3%, ±2%, ±1%, ±0.5% or ±0.05% of the specified value, etc.
[0121] “Optional,” “optional,” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0122] The term "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other aspects. It should be understood that the term "comprising" can include a closed meaning, that is, "consisting of...".
[0123] Unless otherwise indicated, all % are specified by weight throughout this article. In addition, unless otherwise indicated, the weight percentages of diacylglycerols (such as GDO), phosphatidylcholine (such as soybean PC), oxygen-containing organic solvents (such as NMP or DMAC), organic acids (such as maleic acid, methanesulfonic acid, etc.) and compounds shown in general formula I indicated in the context of the present invention are relative to the total weight of (a), (b), (c), (d) and (e).
[0124] When a pharmaceutical composition is referred to herein as "consisting essentially of certain ingredients," the specified ingredient provides the essential properties of the pharmaceutical composition, such as when the specified ingredient constitutes at least 95%, preferably at least 98%, of the pharmaceutical composition.
[0125] Unless the context prohibits, when the active ingredient is indicated herein as a compound of formula I, the compound of formula I in the form of any pharmaceutically acceptable salt is also disclosed. Suitable pharmaceutically acceptable salts are well known in the art, such as halides (especially chlorides), acetates, pamoates and the like. BRIEF DESCRIPTION OF THE DRAWINGS
[0126] Figure 1 A dissolution curve diagram showing the pharmaceutical composition of Example 1, wherein the active ingredients are senabuphine and nalbuphine palmitate;
[0127] Figure 2 Shows the plasma concentration curve of nalbuphine after metabolism of senabuphine and nalbuphine palmitate into nalbuphine in dog plasma. Specific embodiments
[0128] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0129] Preparation Example 1: Preparation method of nalbuphine palmitate (I16a)
[0130]
[0131] Add dichloromethane (40 ml), ethyl acetate (40 ml), z01 (10.0 g), palmitic acid (7.57 g), DMAP (1.72 g), and EDCI (5.93 g) into a 250 ml reaction bottle, heat to 30 °C and react until completion, add 40 ml of water, concentrate to remove dichloromethane, add ethyl acetate to extract, and concentrate the organic phase to obtain the target compound z02 in a yield of 83.78%.
[0132] Add acetonitrile (50 ml), acetic acid (50 ml), intermediate z02 (10.0 g), and Me4NBH(OAc)3 (11.08 g) into a 250 ml reaction bottle, stir at room temperature until the reaction is completed, concentrate at 55°C, add ethyl acetate and sodium carbonate, separate the layers, concentrate the organic phase, and dry to obtain nalbuphine palmitate in a yield of 72%.
[0133] Other compounds of the present invention such as I10a, I12a, I14a, I16b, I16c and I16d were synthesized by a similar method to Preparation Example 1.
[0134] DMAC mentioned in the following examples refers to N,N-dimethylacetamide, NMP refers to N,N-dimethylpyrrolidone; GDO refers to diolein, and soybean PC refers to soybean phosphatidylcholine. The nalbuphine palmitate (purity: 99.19%) and senabuphine (purity: 99.40%) used in the examples. Soybean PC (source: Shenyang Tianfeng Biopharmaceutical Co., Ltd.); diolein (source: Croda, UK).
[0135] Example 1: Prescription and preparation of pharmaceutical composition
[0136] The pharmaceutical compositions of the corresponding compounds were prepared according to the prescription composition in Table 1.1.
[0137] Preparation method:
[0138] The compounds (cenabuphine, nalbuphine palmitate) in the prescription ratio of Table 1.1 and methanesulfonic acid were stirred and dissolved in DMAC, and then GDO was added and stirred evenly, and finally soybean PC was added and heated to 40°C to dissolve, so as to prepare the corresponding pharmaceutical composition.
[0139] Table 1.1 Prescription of drug composition
[0140]
[0141] The obtained pharmaceutical compositions of batches 01a and 05a were subjected to dissolution testing.
[0142] Dissolution method:
[0143] Dissolution apparatus: Agilent 708-DS; High performance liquid chromatography: Shimadzu LC-20AD liquid chromatograph; Basket method; Dissolution medium: pH 7.0 + 0.25% SDS, medium volume 900ml, rotation speed 50rpm; Medium temperature 37°C; Sampling volume 1.5ml; Sampling method: 1.5ml rehydration; Sample amount per basket: 150mg; Sampling time points: 15min, 30min, 1h, 2h, 4h, 5h. HPLC detection was performed and its dissolution curve was calculated. The dissolution curves of the senabuphine pharmaceutical composition (batch 01a) and the nalbuphine palmitate pharmaceutical composition (batch 05a) are as follows: Figure 1 The experimental results show that the in vitro dissolution of the nalbuphine palmitate pharmaceutical composition provided in Table 1.1 is slower than that of senabuphine, indicating that the pharmaceutical composition provided by the present invention has a better sustained-release effect.
[0144] Example 2: Prescription and preparation of pharmaceutical composition
[0145] The pharmaceutical composition was prepared according to the prescription composition in Table 2.1.
[0146] Component 1: Add the prescribed amount of GDO to N,N-dimethylpyrrolidone, then add soybean lecithin, stir and dissolve, and heat to 40°C to speed up the dissolution;
[0147] The second component: add the prescribed amount of methanesulfonic acid to N,N-dimethylpyrrolidone and stir to mix, then add nalbuphine palmitate and dissolve and mix;
[0148] The first component and the second component in each prepared composition were stored separately in 2 ml vials.
[0149] Table 2.1 Prescription of pharmaceutical composition
[0150]
[0151]
[0152] The first component and the second component in the above sample were placed in a 25℃±2℃ / RH60%±5% stability test box for 1 month and in a 2~8℃ refrigerator for 1 month, and then the first component and the second component were mixed and tested for properties and purity. The purity was tested by HPLC. The test results showed that the purity of the above sample did not change after being placed at 25℃ and 2~8℃ for 1 month, indicating that the sample had good stability.
[0153] Example 3: Stability study of pharmaceutical composition
[0154] Table 3.1 Ratio of raw material and auxiliary material prescription
[0155]
[0156] Note: API: refers to active pharmaceutical ingredient, corresponding to senabuphine and nalbuphine palmitate in the table header.
[0157] Add the methanesulfonic acid in the amount prescribed in Table 3.1 to DMAC and stir to mix, then add API (cenabuphine, nalbuphine palmitate) to dissolve and mix to obtain the corresponding pharmaceutical compositions.
[0158] The pharmaceutical compositions of the above batches 01c and 05c were subjected to stability studies. The samples of the two batches were placed under accelerated test conditions (40°C ± 2°C / RH 75% ± 5% stability test box), and the maximum single impurity and total impurity contents were detected on days 0, 15 and 30, respectively. The test results are shown as follows: the total impurities of the senabuphine pharmaceutical composition (batch number 01c) increased by 0.29% and 0.70% on days 15 and 30, respectively, and the maximum single impurity increased by 0.02% and 0.03%, respectively; the total impurities and maximum single impurity increases of nalbuphine palmitate (batch number 05c) on days 15 and 30 were both 0.00% relative to those on day 0;
[0159] The above results show that the pharmaceutical composition of nalbuphine palmitate provided by the present invention has very good stability and better compatibility with pharmaceutical excipients.
[0160] Test Example 1: Metabolic stability study in plasma
[0161] Table 2.1c Test compounds and their preparation
[0162]
[0163]
[0164] The test plasma was canine plasma, and the anticoagulant was EDTA-2K.
[0165] Experimental steps:
[0166] (1) Take 900 μL of acetonitrile in an EP tube, add 100 μL of 10 mM senabuphine stock solution, the final concentration is 1000 μM working solution, and vortex to mix;
[0167] (2) Take 490 μL of blank canine plasma in an EP tube, add 10 μL of the working solution of the test substance to a final concentration of 20 μM, and vortex to mix;
[0168] (3) Place the samples in an air bath at 37°C for 0, 5, 15, 30, 60, 120, and 240 min, with two replicates at each time point;
[0169] (4) Take out 50 μL from the incubation system and add 700 μL of precipitant (acetonitrile containing Verapamil 20.0 ng / mL) for protein precipitation;
[0170] (5) All samples were centrifuged at 8000 rpm for 30 min at 4°C;
[0171] (6) Take 50 μL of the supernatant and add 450 μL of 0.1% formic acid. Vortex to mix well and use a volume of 5 μL for LC-MS / MS analysis.
[0172] The formula for evaluating compound plasma stability is: original drug remaining % = At / A0 × 100%;
[0173] Where At represents the amount of the analyte at the incubation time point; A0 represents the amount of the analyte in the 0h sample.
[0174] Senabuphine is degraded into nalbuphine in the body to exert analgesic effect. The test results are as follows Figure 2 As shown, it was shown that compared with senabuphine, the degradation rate of nalbuphine palmitate was slower than that of senabuphine, indicating that nalbuphine palmitate had better stability in plasma and better sustained-release effect.
[0175] Based on the above ideal embodiments of this application, the relevant staff can make various changes and modifications without departing from the technical concept of this application through the above description. The technical scope of this application is not limited to the content in the specification, and its technical scope must be determined according to the scope of the claims.
Claims
1. A pharmaceutical composition comprising a compound of formula I, It is characterized in that The pharmaceutical composition comprises (a) diacylglycerol, (b) phosphatidylcholine, (c) an oxygen-containing organic solvent, (d) at least one organic acid and (e) a compound represented by general formula I; Wherein, the compound represented by the general formula I has the following structure: Among them, R 1 Selected from: C 9~15 A straight chain or branched chain alkyl group, or H; R 2 Selected from: C 1~6 Straight or branched alkyl, C 3~6 Cycloalkyl, C 2~6 Alkenyl or H; Preferably, the R 1 Selected from C 9 A straight or branched alkyl group, C 10 A straight or branched alkyl group, C 11 A straight or branched alkyl group, C 12 A straight or branched alkyl group, C 13 A straight or branched alkyl group, C 14 A straight or branched chain alkyl group, or C 15 A straight chain or branched alkyl group; Preferably, the R 2 is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or vinyl; Further preferably, the compound represented by the general formula I, wherein R 1 Selected from C 15 A straight chain alkyl group; Further preferably, the compound represented by the general formula I, wherein R 2 is selected from cyclobutyl; More preferably, the compound represented by the general formula I is selected from the following compounds:
2. The pharmaceutical composition according to claim 1, It is characterized in that Mode A: (a) diacylglycerol, (b) phosphatidylcholine and part of (c) oxygen-containing organic solvent are the first component of the pharmaceutical composition, and the remaining (c) oxygen-containing organic solvent, (d) at least one organic acid and (e) the compound represented by general formula I are the second component of the pharmaceutical composition; or Mode B: (a) diacylglycerol, (b) phosphatidylcholine, (c) oxygen-containing organic solvent and (d) at least one acid are the first component of the pharmaceutical composition, and (e) the compound represented by general formula I is the second component of the pharmaceutical composition; and the first component and the second component are stored separately; Preferably, the weight ratio of the oxygen-containing organic solvent in the first component to the oxygen-containing organic solvent in the second component in method A is (0.2-2):1; Preferably, the first component is stored in a first container and the second component is stored in a second container; or the first component and the second component are respectively stored in different compartments of a dual-compartment dispensing device; Further preferably, the first container and the second container are independently selected from vials, ampoules or prefilled syringes, and the prefilled syringe is preferably a prefilled Luer lock syringe; or, the pharmaceutical composition is stored in a double-chamber prefilled syringe, the double-chamber prefilled syringe comprising a front chamber and a rear chamber, the first component is stored in the front chamber, and the second component is stored in the rear chamber, or the first component is stored in the rear chamber, and the second component is stored in the front chamber; Further preferably, before use of the pharmaceutical composition, the first component and the second component are mixed evenly.
3. The pharmaceutical composition according to any one of claims 1 to 2, It is characterized in that The content of the compound represented by the general formula I is 5 to 20% by weight, preferably 7 to 15% by weight; The content of diacylglycerol is 40 to 65% by weight, preferably 50 to 60% by weight; The content of phosphatidylcholine is 4 to 15% by weight, preferably 4 to 10% by weight; The molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1; The content of the oxygen-containing organic solvent is 15 to 50% by weight, preferably 20 to 35% by weight; The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e).
4. The pharmaceutical composition according to any one of claims 1 to 2, It is characterized in that The content of the compound represented by the general formula I is 5 to 10% by weight; The content of diacylglycerol is 50-60% by weight; The content of phosphatidylcholine is 4 to 10% by weight; The content of the oxygen-containing organic solvent is 20 to 35% by weight; The molar ratio of the compound represented by the general formula I to the organic acid is 1.2 to 2.2:1; The weight percentages are relative to the total weight of (a), (b), (c), (d) and (e).
5. The pharmaceutical composition according to any one of claims 1 to 4, It is characterized in that (a) the diacylglycerol is diolein; (b) the phosphatidylcholine is selected from at least one of egg PC, heart PC, brain PC, liver PC, egg yolk PC or soybean PC; (c) the oxygen-containing organic solvent is selected from amides, C 1 -C 3 At least one of alcohols or benzyl alcohol, the amides are selected from at least one of N-methylpyrrolidone, dimethylformamide, 2-pyrrolidone and dimethylacetamide; (d) the organic acid is at least one of methanesulfonic acid, maleic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, and citric acid; More preferably, the diacylglycerol is selected from diolein; the phosphatidylcholine is selected from soybean phosphatidylcholine; the oxygen-containing organic solvent is selected from DMAC and / or NMP; and the organic acid is selected from methanesulfonic acid, and optionally further comprises maleic acid.
6. The pharmaceutical composition according to claim 1, It is characterized in that The pharmaceutical composition comprises a first component and a second component, and the first component and the second component are stored separately, wherein the first component comprises 50-60 weight % of dioleyl glycerol, 4-15 weight % of soybean PC and 5-20 weight % of dimethylacetamide; the second component comprises 10-30 weight % of dimethylacetamide, 7-15 weight % of the compound represented by general formula I, and methanesulfonic acid, and optionally further comprises maleic acid; Alternatively, the first component comprises 50-60 wt% of dioleyl glycerol, 4-15 wt% of soybean PC, 20-35 wt% of dimethylacetamide, and methanesulfonic acid, and optionally further comprises maleic acid; the second component comprises 7-15 wt% of the compound represented by general formula I; The molar ratio of the compound represented by general formula I to methanesulfonic acid is 1.2 to 2.2:1; the weight percentage is relative to the total weight of (a), (b), (c), (d) and (e); Preferably, the first component is stored in a first container and the second component is stored in a second container; or the first component and the second component are respectively stored in different compartments of a dual-compartment dispensing device; Further preferably, the first container and the second container are independently selected from vials, ampoules or prefilled syringes, and the prefilled syringe is preferably a prefilled Luer lock syringe; alternatively, the pharmaceutical composition is stored in a double-chamber prefilled syringe, the double-chamber prefilled syringe comprising a front chamber and a rear chamber, the first component is stored in the front chamber, the second component is stored in the rear chamber, or the first component is stored in the rear chamber, and the second component is stored in the front chamber; further preferably, before use of the pharmaceutical composition, the first component and the second component are mixed evenly.
7. The pharmaceutical composition according to any one of claims 1 to 2, It is characterized in that The pharmaceutical composition comprises: 7 to 15% by weight of the compound represented by the general formula I; 20 to 35% by weight of dimethylacetamide; 50-60% by weight of diolein; 4-15% by weight of soybean PC; and methanesulfonic acid, optionally also maleic acid; The molar ratio of the compound represented by general formula I to methanesulfonic acid is 1.2-2.2:
1.
8. The pharmaceutical composition according to any one of claims 1 to 7, It is characterized in that The unit dosage of the pharmaceutical composition contains 50 to 200 mg, preferably 100 to 150 mg of the compound of formula I.
9. The pharmaceutical composition according to any one of claims 1 to 8, It is characterized in that The compound represented by the general formula I is selected from:
10. The compound represented by the general formula I, It is characterized in that It has the following structure: Among them, R 1 Selected from: C 9~15 A straight chain or branched chain alkyl group, or H; R 2 Selected from: C 1~6 Straight or branched alkyl, C 3~6 Cycloalkyl, C 2~6 Alkenyl or H; Preferably, the R 1 Selected from C 9 A straight or branched alkyl group, C 10 A straight or branched alkyl group, C 11 A straight or branched alkyl group, C 12 A straight or branched alkyl group, C 13 A straight or branched alkyl group, C 14 A straight or branched chain alkyl group, or C 15 A straight chain or branched alkyl group; Preferably, the R 2 is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or vinyl; Further preferably, the compound represented by the general formula I, wherein R 1 Selected from C 15 A straight chain alkyl group; Further preferably, the compound represented by the general formula I, wherein R 2 is selected from cyclobutyl; further preferably, the compound represented by the general formula I is selected from:
11. The pharmaceutical composition according to any one of claims 1 to 9, or the use of the compound according to claim 10 in the preparation of a medicament for treating pain; Preferably, the pain is selected from surgical pain or long-term chronic pain; Further preferably, the pain is selected from pain caused by hernia surgery, hemorrhoid surgery, abdominal surgery, plastic surgery, orthopedic surgery, ENT surgery, cancer pain, chronic back pain or chronic joint pain.
12. A method for preparing the pharmaceutical composition according to any one of claims 1 to 9, The following steps are involved: Method S1: adding the compound of formula I and an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then adding acylglycerol, and finally adding phosphatidylcholine, and dissolving them to obtain the product; or, Method S2: first add an organic acid in a prescribed ratio to an oxygen-containing organic solvent, then add acylglycerol and phosphatidylcholine in sequence, stirring and dissolving, and finally add the compound represented by general formula I, stirring and dissolving to obtain the product; or, Method S3: adding diacylglycerol in a prescribed ratio to a portion of an oxygen-containing organic solvent, and then adding phosphatidylcholine, stirring and dissolving, as a first component; Adding an organic acid in a prescribed ratio to the remaining amount of an oxygen-containing organic solvent and stirring to mix well, then adding the compound represented by the general formula I and dissolving and mixing well to form the second component; or, Method S4: adding an organic acid in a prescribed ratio to an oxygen-containing organic solvent and stirring to mix well, then adding acylglycerol and phosphatidylcholine and stirring to dissolve, as a first component; The compound of formula I in the prescribed proportion is used as the second component; Preferably, in the above method, when phosphatidylcholine is added to dissolve, the mixture is first heated to a temperature not exceeding 45°C.
Citation Information
Patent Citations
Packaged products, inserts and compartments for aseptic mixing of substances, along with methods for use therewith
CN102482023A
Pharmaceutical composition containing dinalbuphine sebacate
WO2023020608A1
